Neoadjuvant immunotherapy: moving beyond melanoma

The very encouraging responses to neoadjuvant immunotherapy in trials across a range of cancers are unparalleled and promise a new standard of care in the future. Speaking at the 2021 COSA ASM, Dr Elizabeth Ahern said that while both adjuvant and neoadjuvant treatment are given with the intention to improve outcomes, neoadjuvant treatment additionally provides ...

Already a member?

Login to keep reading.

© 2021 the limbic